Welcome to our dedicated page for BioVie news (Ticker: $BIVI), a resource for investors and traders seeking the latest updates and insights on BioVie stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioVie's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioVie's position in the market.
BioVie Inc. (NASDAQ: BIVI) secured up to $13.1 million from the U.S. Department of Defense for a Phase 2b clinical trial evaluating bezisterim (NE3107) in treating long COVID symptoms. Long COVID is a condition where symptoms persist post SARS-CoV-2 infection. The trial aims to assess the drug's effectiveness in reducing neurological symptoms associated with long COVID. Bezisterim, an anti-inflammatory and insulin-sensitizer capable of permeating the blood-brain barrier, targets inflammation, a key factor in long COVID. The trial is expected to begin in early 2025 and includes 200 patients.
